MGMT and idiopathic pulmonary fibrosis: Treating IPF fibroblasts with the DNA methylation inhibitor 5-aza-2′-deoxycytidine resulted in increased expression of CDKN2B and CARD10, but not MGMT (Figure 3E), consistent with the hypothesis that increased methylation down-regulates expression of CKDN2B and CARD10.